By improving these metabolic parameters, GLP-1 RAs reduce the concentrations of insulin-like growth factor (IGF) binding protein, resulting in lower levels of free IGF-1 in cells and tissues, indirectly reduce the risk of esophageal cancer (19). This evidence concerns the gene GLP1R and esophageal cancer.